Dr. Michael Postow is a New York City oncology researcher who serves as chief of the melanoma service with the Memorial Sloan Kettering (MSK) Cancer Center. His efforts focus on coming up with better treatments for patients with advanced melanoma. Dr. Michael Postow also serves as co-director of the Melanoma Disease Management Team, which includes nurses, researchers, and medical oncologists with experience at the forefront of melanoma advances.
Dr. Postow directs several medical research projects, including ones that focus on what makes immune checkpoint blockade more effective. He works with many different pharmaceutical and biotech companies to guide clinical trials focused on improving systemic treatments for patients with melanoma.
Dr. Postow earned the Lynx Group's “40 Under 40 in Cancer” award in 2020 and received the Julia Zelmanovich Young Alumni Award from the New York University Grossman School of Medicine. He has served on Committees of the American Society of Clinical Oncology and frequently speaks at international meetings of researchers and clinicians caring for patients with advanced melanoma. His research has been funded by the Melanoma Research Alliance and the Conquer Cancer Foundation.